产品
编 号：F144930
分子式：C56H79N15O9
分子量：1106.32
分子式：C56H79N15O9
分子量：1106.32
产品类型
规格
价格
是否有货
结构图
CAS No: 138147-78-1
产品详情
生物活性：
RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist. RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice.
体内研究：
RC-3095 impairs aversive but not recognition memory in Wistar male rats.RC-3095 (0.3 mg/kg or 1 mg/kg; S.C.) shows anti-inflammatory effects in 2 experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA). Arthritic mice treated with RC-3095 show a significant reduction in the concentrations of IL-17, IL-1 , and TNF, and showed a diminished expression of GRPR.Animal Model:Male Balb/c wild-type mice (weighing 18-25 gm) with AIA model; Male DBA/1J inbred mice (weighing 18-25 gm) with CIA model
Dosage:1 mg/kg for AIA studies; 0.3 mg/kg or 1 mg/kg for CIA studies
Administration:Injected SC twice a day for a total of 2 or 10 days for AIA studies; Administered SC twice a day for 10 days after the onset of the disease for CIA studies
Result:Reduced neutrophil migration, mechanical hy pernociception, and proteoglycan loss in mice with AIA;Led to a significant reduction in arthritis clinical scores and the severity of disease in the CIA model.
RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist. RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice.
体内研究：
RC-3095 impairs aversive but not recognition memory in Wistar male rats.RC-3095 (0.3 mg/kg or 1 mg/kg; S.C.) shows anti-inflammatory effects in 2 experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA). Arthritic mice treated with RC-3095 show a significant reduction in the concentrations of IL-17, IL-1 , and TNF, and showed a diminished expression of GRPR.Animal Model:Male Balb/c wild-type mice (weighing 18-25 gm) with AIA model; Male DBA/1J inbred mice (weighing 18-25 gm) with CIA model
Dosage:1 mg/kg for AIA studies; 0.3 mg/kg or 1 mg/kg for CIA studies
Administration:Injected SC twice a day for a total of 2 or 10 days for AIA studies; Administered SC twice a day for 10 days after the onset of the disease for CIA studies
Result:Reduced neutrophil migration, mechanical hy pernociception, and proteoglycan loss in mice with AIA;Led to a significant reduction in arthritis clinical scores and the severity of disease in the CIA model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备